Learn more

BRISTOL-MYERS SQUIBB COMPANY

Overview
  • Total Patents
    1,296
  • GoodIP Patent Rank
    1,714
  • Filing trend
    ⇩ 46.0%
About

BRISTOL-MYERS SQUIBB COMPANY has a total of 1,296 patent applications. It decreased the IP activity by 46.0%. Its first patent ever was published in 1992. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are BRISTOL MYERS SQUIBB COMPANY UNA CORPORACIÓN DEL ESTADO DE DELAWARE, EISAI R&D MAN CO LTD and MERCK SHARP & DOHME.

Patent filings per year

Chart showing BRISTOL-MYERS SQUIBB COMPANYs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Macor John E 89
#2 Scola Paul Michael 86
#3 Mull Eric 60
#4 Sun Li-Qiang 58
#5 Gillis Eric P 57
#6 Corte James R 56
#7 Ewing William R 54
#8 Zhao Qian 52
#9 Pinto Donald J P 47
#10 Wang Yufeng 46

Latest patents

Publication Filing date Title
WO2020172658A1 Methods of isolating a protein
WO2020168149A1 Substituted amide compounds useful as farnesoid x receptor modulators
WO2020168148A1 Substituted bicyclic compounds as farnesoid x receptor modulators
WO2020168143A1 Substituted bicyclic compounds as farnesoid x receptor modulators
WO2020163415A1 Synthesis of 1,2,5-tri-0-benz0yl-3-dibenzylamin0-3-de0xyrib0se as intermediate for producing 3'-amino-3'-deoxyadenosine and 3'-amino-3'-deoxyguanosine and the protected derivatives thereof
WO2020159904A1 Amide-disubstituted pyridine or pyridazine compounds
WO2020123425A2 Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
EP3710440A1 Substituted indole compounds
KR20200084880A How to treat a tumor
KR20200084879A Pyrrolopyrazine derivatives as alpha V integrin inhibitors
KR20200083529A Alkene spirocyclic compounds as farnesoid X receptor modulators
US2020255785A1 Online biomass capacitance monitoring during large scale production of polypeptides of interest
WO2018017529A1 Radioligands for imaging the ido1 enzyme
WO2018013772A1 Monocyclic heteroaryl substituted compounds
WO2018009627A1 Spiro-fused cyclic ureas as inhibitors of rock
WO2018009625A1 Spirolactams as inhibitors of rock
AU2017292758A1 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
WO2017210335A1 Imaging methods using 18f-radiolabeled biologics
US2017326249A1 Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
WO2017181034A1 Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody